RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Figure 5

Forrest plot of hazard ratios for PFS of the subsequent first-line chemotherapy patients. Except for plasma RAS/BRAF mutations, other clinical factors including age, gender, primary tumor site, perineural invasion, vascular tumor thrombus, histologic grade, T stage, and N stage were not significantly associated with PFS.